A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 13 Jul 2018 Status changed from not yet recruiting to recruiting.
- 16 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jun 2018.
- 18 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.